by Alyssa Lee | Jun 1, 2024
DelRicht Research is proud to highlight the outstanding performance of our investigators and site teams in a Phase 4 clinical trial focused on attention-deficit/hyperactivity disorder (ADHD) in children ages 4-12. Over the course of a 14-month enrollment period, our...
by Alyssa Lee | Jul 29, 2022
On July 29, 2022, the U.S. Food and Drug Administration (FDA) approved Arcutis Biotherapeutics’ ZORYVE™ (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in individuals 12 years and older, including in sensitive intertriginous areas. This...
by Alyssa Lee | Feb 21, 2020
NEW ORLEANS, LA – The U.S. Food and Drug Administration (FDA) has approved NEXLETOL™ (bempedoic acid), a once-daily, oral, non-statin LDL-cholesterol (LDL-C) lowering therapy developed by Esperion Therapeutics. The treatment is indicated as an adjunct to diet...
by Alyssa Lee | Mar 2, 2018
NEW ORLEANS, LA – The U.S. Food and Drug Administration (FDA) has approved OTIPRIO® (ciprofloxacin otic suspension) 6% for the treatment of acute otitis externa (AOE), also known as swimmer’s ear, in patients aged 6 months and older. This approval marks the...
by Alyssa Lee | Sep 28, 2017
NEW ORLEANS, LA – The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for AMITIZA® (lubiprostone), granting it Priority Review designation for the treatment of pediatric functional constipation in...
